Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RMD1508
- Development stage
- Preclinical
- Lead developer
- Remedium Bio
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
RMD1508 is a preclinical gene therapy candidate being developed by Remedium Bio (formerly Remedium Technologies) for the treatment of cardiovascular diseases. The program utilizes Remedium's proprietary delivery platforms, which include adeno-associated virus (AAV) vectors and lipid nanoparticle (LNP) formulations. As of early 2024, RMD1508 is in the IND-enabling stage of development. While the specific genetic target or molecular mechanism of action has not been publicly disclosed by the sponsor, the program is part of a broader pipeline focused on treating chronic diseases through long-term therapeutic protein expression.
Beyond the preview
Go deeper on RMD1508.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RMD1508.